ArticleNature nanotechnology2026
AND logic nanoparticle for precision immunotherapy of metastatic cancers.
Article in Nature nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Smart mesoporous silica nanoparticles for precision cancer therapy: Tumor targeting and stimuli-responsive controlled release.Smart molecules : open access · 2026Review
- Review
- Applications of synthetic biology in biomedicine.Molecular biomedicine · 2026Review
- Tumor microenvironment-specific nanomedicine: from biology-driven to multi-omics-guided precision engineering.Journal of hematology & oncology · 2026Review
- Oxidative Stress-Guided Gold Nanoparticles for Cancer Theranostics.Antioxidants (Basel, Switzerland) · 2026Review
- Logic‑gated nanomedicine activates STING to boost metastatic tumour immunotherapy.Nature nanotechnology · 2026Article
- Advancements in polymer-based drug delivery systems targeting the tumor microenvironment for immunotherapy of triple-negative breast cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Success in systemic immunotherapy against metastatic cancer hinges on the ability to achieve tumour-specific immune activation over normal tissues. Single-gate stimuli-responsive systems are not adequate at differentiating tumour versus normal tissue signals. Here we report an AND-gated nanoparticle that requires acidic pH and hypoxia signals to activate the stimulator of interferon genes (STING) pathway in systemic therapy of metastatic cancers. The dual stimuli-responsive nanoparticle consists of a small-molecule STING agonist conjugated to a pH-sensitive polymer through a hypoxia-sensitive linker. Biochemical analyses confirmed the (pH-hypoxia) AND logic truth table in STING activation. The nanoparticle agonist significantly reduced metastatic burdens in multiple immune-cold tumour models while exhibiting minimal systemic toxicity. Mechanistic investigation revealed that STING activation in tumour-resident type I dendritic cells drives CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.